22 Dec 2017 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Grant of Options
Alderley Park, December 22 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, today announces that on 21 December 2017 options over 500,000 ordinary shares of 1p each in the share capital of the Company, were granted to Dominic Jackson, Chief Financial Officer, under Redx's Enterprise Management Incentive Scheme.
One-third of the options are exercisable at a price of 22p and will vest immediately, one-third are exercisable at a price of 33p and will vest on the 1 year anniversary of the grant, and one-third are exercisable at a price of 50p and will vest on the 2 year anniversary of the grant. None of these options will become exercisable until the second anniversary of grant.
In addition, options over 3,260,000 ordinary shares of 1p each in the share capital of the Company were granted to the management and staff of the Company, also under Redx's Enterprise Management Incentive Scheme. These options are exercisable at the same prices and on the same terms as above.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Executive Chairman | |
Cantor Fitzgerald Europe (Nominated Advisor & Broker) | T: +44 20 7894 7000 |
Phil Davies | |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
About Redx Pharma
Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, Redx pursues targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, the Company is focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas Redx's aim is to develop drugs whose profile suggests they will be best in class, if not first in class.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | ||
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a. | Name | Dominic Jackson |
2 | Reason for notification |
|
a. | Position/Status | Chief Financial Officer |
b. | Initial notification/ Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a. | Name | Redx Pharma Plc |
b. | LEI | 213800HMS4EBXO589Y37 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a. | Description of the financial instrument, type of instrumentIdentification Code | Options over Ordinary Shares of 1p each ISIN: GB00BSNB6S51 |
b. | Nature of the transaction | Grant of options under the EMI Share Scheme |
c. | Price(s) and volume(s) | Option awarded over 166,667 shares at an exercise price of 22p per share
Option awarded over 166,667 shares at an exercise price of 33p per share
Option awarded over 166,666 shares at an exercise price of 50p per share |
d. | Aggregated information - Aggregated Volume - Price | N/A - Single Transaction |
e. | Date of the transaction | 21/12/17 |
f. | Place of the transaction | Outside of trading venue |